Transgene Biotek will sell one of its bio-generic products 'Erythropoietin', to Tss Export GmbH for a total consideration of $5 million (over Rs 26 crore). The management of Transgene has formalised the sale of technology of one of its bio-generic products, Erythropoietin to 'Tss Export GmbH FZE' for a total consideration of $5 million.
Erythropoietin is a hormone produced by the kidney that promotes the formation of red blood cells in the bone marrow. This sale of technology is expected to be completed during a period of approximately 5-6 months. With the market for Erythropoietin set to become very competitive, the management of Transgene has decided to monetise some of the dormant technologies through either out-licensing or strategic partnerships within and outside India. The company had earlier out-licensed two of its technologies - a recombinant Hepatitis B Vaccine to one of the largest vaccine producers in the world, and more recently Orlistat to one of the biggest Indian pharma companies with a significant presence on the global arena.
Company Name | CMP |
---|---|
Apollo Hospital Ent. | 7001.50 |
Max Healthcare Inst | 1105.00 |
Narayana Hrudayalay | 1800.15 |
Aster DM Healthcare | 512.55 |
Global Health | 1195.00 |
View more.. |